LONE TREE, CO--(Marketwire - August 03, 2011) -
| Highlighted Links |
|
Zynex, Inc. (OTCBB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announces its second quarter 2011 financial results.
The Company generated record net revenues of $8,395,000 for the three months ended June 30, 2011, which represents a 46% increase over second quarter 2010 net revenue and a 27% increase over the first quarter of 2011. Year to date net revenue of $15,028,000 increased 42% over the prior year to date net revenue. Thomas Sandgaard, CEO, stated “The aggressive expansion of our sales force has resulted in a significant increase in orders and respective revenue growth. We plan to add sales representatives throughout the remainder of 2011 in an effort to continue to drive our top-line growth.”
The Company reported a second quarter 2011 gross profit of $6,668,000, which reflects a 79% gross profit percentage, unchanged from the second quarter 2010 gross profit percentage. Selling, general and administrative (SG&A) expenses in the second quarter of 2011 totaled $5,769,000 compared to $4,390,000 in the second quarter of 2010. The 31% increase in SG&A during the second quarter of 2011 as compared to the second quarter of 2010, was a direct result of specific investments made to expand the sales force and improve billing and reimbursement department efficiencies. The Company reported second quarter 2011 income from operations of $899,000, income before income tax of $822,000 and net income of $484,000, versus second quarter 2010 income from operations of $130,000, income before income tax of $82,000 and net income of $30,000.
Thomas Sandgaard, CEO stated: “Overall demand for our products remains robust, as we continued strong top-line growth for the quarter. Previous investments made in our infrastructure to accommodate our current and anticipated sales growth have begun to payoff, as our second quarter 2011 net income has increased significantly over the prior quarter in 2010 and increases in our net revenue for the respective periods have out paced that of our SGA expenses. SGA expenses increased 31% over the second quarter of 2010 and just 8% over the first quarter of 2011.”
Mr. Sandgaard continued: “Our long term goal is to diversify our revenue base currently being driven by our Zynex Medical, electrotherapy subsidiary, through our additional subsidiaries, Zynex Monitoring Solutions and Zynex NeuroDiagnostics, which should provide us access to new markets. We continue to make progress on our blood volume monitor device, currently being developed in our Zynex Monitoring Solutions subsidiary, in which we have a working prototype preparing for clinical evaluations that will be used to provide substantiation for FDA submission and international regulatory clearance. This unique device will serve, what we believe, is a currently un-met need in the market for safer surgeries and safer monitoring of patients during recovery. We have also been studying the markets for both Zynex NeuroDiagnostics and Zynex Monitoring Solutions and have identified potential growth opportunities.”
Outlook:
The Company has refined its prior guidance by raising anticipated annual net revenue guidance to between $32 million and $34 million and narrowing the range of its net income per diluted share guidance to between $0.08 and $0.10 for 2011.
Conference Call and Webcast Information:
Zynex, Inc. will host an earnings conference call and webcast at 9:00 a.m. MST (11:00 a.m. EST) today to discuss its second quarter 2011 results. Please note questions can only be submitted via the webcast user interface. Parties without access to the internet may join the presentation in listen only mode by dialing the toll free number provided below.
Webcast Information- http://www.visualwebcaster.com/event.asp?id=81276
Conference Call Information - 888-208-1814, pass-code 3744529
Highlights from the second quarter ended 2011 condensed consolidated financial statements:
(unaudited, amounts in thousands, except per share amounts)
Three months ended Six months ended ----------------------- ----------------------- June 30, June 30, June 30, June 30, 2011 2010 2011 2010 ----------- ----------- ----------- ----------- Net revenue $ 8,395 $ 5,742 $ 15,028 $ 10,617 Gross profit 6,668 4,520 11,857 8,399 Income from operations 899 130 760 162 Income before income tax 822 82 625 18 Net income (loss) 484 30 374 (37) Adjusted EBITDA (1) 1,148 783 1,253 1,324 Net income per share - diluted $ 0.02 * $ 0.01 $ ** Weighted-average number of common shares outstanding -diluted 30,756,717 30,513,285 30,694,216 30,505,347 * Less than $0.01 per share ** Less than $(0.01) per share
(1) Reconciliation of unaudited U.S. Generally Accepted Accounting Principles (GAAP) Net income (loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization (Adjusted-EBITDA)
Three months ended Six months ended -------------------- -------------------- June 30, June 30, June 30, June 30, 2011 2010 2011 2010 --------- --------- --------- --------- Net income (loss) $ 484 $ 30 $ 374 $ (37) Interest expense net and loss on extinguishment of debt 79 50 137 128 Income taxes 338 52 251 55 Depreciation and amortization 209 210 412 422 Deferred rent (56) 282 (111) 564 Loss on disposal of equipment - 46 - 18 Stock-based expense 94 113 190 174 --------- --------- --------- --------- Adjusted EBITDA $ 1,148 $ 783 $ 1,253 $ 1,324 ========= ========= ========= =========
About Zynex
Zynex, Inc. (founded in 1996), operates under three primary business segments; Zynex Medical, Zynex NeuroDiagnostics and Zynex Monitoring Solutions. Zynex Medical engineers, manufactures, markets and sells its own design of electrotherapy medical devices for standard digital electrotherapy, used for pain relief, pain management and stroke and spinal cord injury rehabilitation. Zynex Medical’s product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company’s mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. Zynex NeuroDiagnostics, currently in the development stage, has been established to market EMG, EEG, sleep pattern, auditory and nerve conductivity neurological diagnosis devices through product development or acquisitions. Zynex Monitoring Solutions, currently in the development stage, has been established to develop and market medical devices for non-invasive cardiac monitoring.
For additional information please visit: http://www.ir-site.com/zynex/default.asp.
Safe Harbor Statement
Certain statements in this release are “forward-looking” and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, our ability to engage additional sales representatives, the success of such additional sales representatives, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described in our filings with the Securities and Exchange Commission including the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2010.
ZYNEX, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (AMOUNTS IN THOUSANDS, EXCEPT NUMBER OF SHARES) June 30, December 31, 2011 2010 ------------ ------------ (UNAUDITED) ASSETS Current Assets: Cash $ 783 $ 602 Accounts receivable, net 9,513 7,309 Inventory 3,751 3,641 Prepaid expenses 136 145 Deferred tax asset 917 794 Other current assets 63 41 ------------ ------------ Total current assets 15,163 12,532 Property and equipment, net 3,239 2,906 Deposits 201 174 Deferred financing fees, net 91 89 ------------ ------------ Total assets $ 18,694 $ 15,701 ============ ============ LIABILITIES AND STOCKHOLDERS’ EQUITY Current Liabilities: Line of credit $ 3,204 $ 1,270 Current portion of capital lease obligations 100 93 Accounts payable 1,458 1,313 Income taxes payable 911 1,103 Accrued payroll and payroll taxes 794 572 Deferred rent 259 221 Other accrued liabilities 1,367 980 ------------ ------------ Total current liabilities 8,093 5,552 Capital lease obligations, less current portion 274 327 Deferred rent 1,303 1,452 Deferred tax liability 230 188 ------------ ------------ Total liabilities 9,900 7,519 ------------ ------------ Stockholders’ Equity: Preferred stock; $.001 par value, 10,000,000 shares authorized, no shares issued or outstanding - - Common stock, $.001 par value, 100,000,000 shares authorized, 30,775,034 (June 2011) and 30,604,167 (December 2010) shares issued and outstanding 31 31 Paid-in capital 4,940 4,702 Retained earnings 3,823 3,449 ------------ ------------ Total stockholders’ equity 8,794 8,182 ------------ ------------ Total liabilities and stockholders’ equity $ 18,694 $ 15,701 ============ ============ ZYNEX, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED, AMOUNTS IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) Three Months Ended Six Months Ended June 30, June 30, ------------------------ ------------------------ 2011 2010 2011 2010 ----------- ----------- ----------- ----------- Net revenue: Rental $ 2,447 $ 2,335 $ 4,895 $ 4,606 Sales 5,948 3,407 10,133 6,011 ----------- ----------- ----------- ----------- 8,395 5,742 15,028 10,617 ----------- ----------- ----------- ----------- Cost of revenue: Rental 392 258 726 533 Sales 1,335 964 2,445 1,685 ----------- ----------- ----------- ----------- 1,727 1,222 3,171 2,218 ----------- ----------- ----------- ----------- Gross profit 6,668 4,520 11,857 8,399 Selling, general and administrative expense 5,769 4,390 11,097 8,237 ----------- ----------- ----------- ----------- Income from operations 899 130 760 162 ----------- ----------- ----------- ----------- Other income (expense): Interest income 1 3 1 4 Interest expense and loss on extinguishment of debt (80) (53) (138) (132) Other income (expense) 2 2 2 (16) ----------- ----------- ----------- ----------- (77) (48) (135) (144) ----------- ----------- ----------- ----------- Income before income tax 822 82 625 18 Income tax expense (338) (52) (251) (55) ----------- ----------- ----------- ----------- Net income (loss) $ 484 $ 30 $ 374 $ (37) =========== =========== =========== =========== Net income (loss) per share: Basic $ 0.02 $ * $ 0.01 $ ** =========== =========== =========== =========== Diluted $ 0.02 $ * $ 0.01 $ ** =========== =========== =========== =========== * Less than $0.01 per share ** Less than ($0.01) per share Weighted average number of common shares outstanding: Basic 30,756,717 30,513,285 30,694,216 30,505,347 =========== =========== =========== =========== Diluted 31,025,478 30,702,944 30,957,206 30,716,349 =========== =========== =========== =========== ZYNEX, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED - AMOUNTS IN THOUSANDS) Six Months Ended June 30, -------------------- 2011 2010 --------- --------- Cash flows from operating activities: Net income (loss) $ 374 $ (37) Adjustments to reconcile net income (loss) to net cash used in operating activities: Depreciation expense 389 401 Provision for losses on uncollectible accounts receivable 630 102 Amortization of financing fees 23 21 Issuance of common stock for services 44 48 Provision for obsolete inventory - (9) Deferred rent (111) 564 Net loss on disposal of equipment - 18 Employee stock-based compensation expense 146 126 Deferred tax benefit (81) (355) Changes in operating assets and liabilities: Accounts receivable (2,834) (1,257) Inventory (93) (868) Prepaid expenses 9 107 Other current assets (49) (19) Accounts payable 145 (25) Accrued liabilities 609 177 Income taxes payable (192) (545) --------- --------- Net cash used in operating activities (991) (1,551) --------- --------- Cash flows from investing activities: Proceeds received in lease termination - 108 Purchases of equipment and inventory used for rental (739) (224) --------- --------- Net cash used in investing activities (739) (116) --------- --------- Cash flows from financing activities: Net borrowings from line of credit 1,934 1,087 Issuance of common stock 48 - Deferred financing fees (25) (90) Payments on capital lease obligations (46) (146) --------- --------- Net cash provided by financing activities 1,911 851 --------- --------- Net increase (decrease) in cash 181 (816) Cash at beginning of period 602 863 --------- --------- Cash at end of period $ 783 47 ========= ========= Supplemental cash flow information: Interest paid $ 102 $ 51 Income taxes paid $ 525 $ 955 Supplemental disclosure of non-cash investing and financing activities: Equipment acquired through capital lease $ - $ 334
Contact:
Zynex, Inc.
Anthony Scalese
CFO
303-703-4906
Digg this
Bookmark with del.icio.us
Add to Newsvine
Technorati: 
